FT Vest美國股票深度緩衝主動型ETF-3月 DMAR 深 滬
交易中 06-25 12:04:25 美东时间
44.4972
-0.023
-0.05%
華盛通- 最 高44.53
- 今 開44.525
- 成交量 3534股
- 最 低 44.49
- 昨 收 44.52
- 總市值 4.18亿
- 52周最高 44.80
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 39.5101
- 委 比 0.00%
- 總股本 940.00万
- 歷史最高 44.80
- 量 比 0.08
- 振 幅 0.09%
- 歷史最低 29.15
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AbbVie's Skyrizi wins EU approval for pediatric plaque psoriasis
AbbVie (ABBV) Tuesday said that the European Commission has approved Skyrizi (risankizumab) for the treatment of children and adolescents six years of age and older with moderate to severe plaque psor...
06-23 17:01
Avenue Supermarts Opens 501st DMart Store in GIFT City, Gandhinagar
Avenue Supermarts Ltd. ( ($IN:DMART) ) has issued an update. Avenue Supermarts ...
06-21 17:22
BRIEF-CSG's Federal Unit Signs Landmark Agreement With U.S. Army To Accelerate High-Performance Ammunition
BRIEF-CSG's Federal Unit Signs Landmark Agreement With U.S. Army To Accelerate High-Performance Ammunition June 1 (Reuters) - CSG NV CSG.AS : DEFENCE GROUP CSG'S UNIT FEDERAL SIGNS LANDMARK AGREEMENT WITH U.S. ARMY TO ACCELERATE HIGH-PERFORMANCE AMMUNITION CSG'S FEDERAL SAYS IT HAS EXECUTED AN AGREE
06-01 17:11
Fennec Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Fennec Pharmaceuticals (NASDAQ:FENC) released first-quarter financial results a...
05-14 21:32
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand
Fennec Pharmaceuticals Q1 sales rise 73% on PEDMARK demand Overview US specialty pharma's Q1 product sales rose 73% yr/yr on higher PEDMARK adoption Company posted net income of $201,000, reversing a loss a year ago Growth driven by expanded field sales and increased demand for PEDMARK Outlook Compa
05-14 18:41
Artiva Biotherapeutics Stock Slides Despite Positive Trial Data
Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.
05-09 00:20
Bristol Myers Squibb Says European Commission Grants Approval To Sotyktu, Alone Or In Combination With Methotrexate, For Treatment Of Active Psoriatic Arthritis In Adults
In the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as
05-08 19:00
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults
BMS wins EU approval for Sotyktu to treat active psoriatic arthritis in adults European Commission granted marketing authorization for Sotyktu (deucravacitinib) to treat active psoriatic arthritis in adults with inadequate response or intolerance to prior DMARD therapy. Label covers use as monothera
05-08 18:59
Avenue Supermarts Files Fiscal 2026 Investor Presentation with Stock Exchanges
Avenue Supermarts Ltd. ( ($IN:DMART) ) has issued an announcement. Avenue Super...
05-02 20:33
BRIEF-Landmark Bancorp Files Non-Timely 10-K With U.S. SEC
BRIEF-Landmark Bancorp Files Non-Timely 10-K With U.S. SEC April 1 (Reuters) - Landmark Bancorp Inc LARK.O : LANDMARK BANCORP INC FILES NON-TIMELY 10-K WITH U.S. SEC LANDMARK BANCORP - TO BEGIN INTERNAL PROBE WITH OUTSIDE COUNSEL INTO MISCONDUCT ALLEGATIONS INVOLVING NON-EXECUTIVE EMPLOYEE AT LANDMA
04-01 18:56
